Leah M. Santacroce

Dec 19, 2024 | acrjournals.onlinelibrary.wiley.com | Hallie Altwies |Leah M. Santacroce |Javier Marrugo |Jacklyn Stratton |Jack Elias Ellrodt |Robert S. Rudin | +1 more

INTRODUCTION Close monitoring of disease activity and management of long-term medications are essential aspects of managing chronic conditions, such as rheumatoid arthritis (RA). In clinical care, treatment recommendations are primarily based on patient and physician assessments of disease activity at the time of a visit.

Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more

The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).

Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more

The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).

Jun 24, 2024 | arthritis-research.biomedcentral.com | Katherine P Liao |Pamela M Rist |Jon Giles |Leah M. Santacroce |Margery A Connelly |Robert J Glynn | +4 more

The overall study design and the primary results of the TARGET study have been previously published [24, 25]. Briefly, the trial included 138 RA patients, men ≥45 years of age and women ≥50 years of age with a disease activity score 28 with CRP (DAS28-CRP) > 3.2 (moderate disease activity). All subjects must have been treated with MTX ≥15 mg once a week at a stable dose for ≥ 4 weeks prior to their screening visit (or ≥7.5 mg once a week for ≥8 weeks with documented intolerance).

Dec 13, 2023 | acrjournals.onlinelibrary.wiley.com | Daniel Solomon |Hallie Altwies |Leah M. Santacroce |Jack Elias Ellrodt

Supporting Information Filename Description art42774-sup-0001-Disclosureform.pdfPDF document, 496.2 KB Disclosure Form art42774-sup-0002-FigureS1.docxWord 2007 document , 17.9 KB Supplementary Figure 1: Inbox Messages Sent to Rheumatologists by App art42774-sup-0003-Tables.docxWord 2007 document , 14.1 KB Supplementary Table 1: Baseline Characteristics of consented RA patients who used app and never used the app Supplementary Table 2: Laboratory evaluations and medication changes around the...